Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic malignancies characterized by peripheral blood cytopenias resulting from ineffective hematopoiesis. MDS is associated with a risk for progression to acute myeloid leukemia (AML). Progress in the field of this disease aims at decreasing the transfusion burden, delaying progression to AML, improving the quality-of-life (QoL) of patients and extending the survival. Here, we report some recent advances presented at the 60th Annual Meeting of the American Society of Hematology (ASH).

(BELG J HEMATOL 2019;10(1):24–30)